Delta133p53 Isoform Detection for Metastatic Cancer Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for breast and colon cancers lack specificity in predicting metastatic potential, leading to inadequate treatment strategies and ineffective chemotherapy targeting, as they do not adequately account for the heterogeneity among patients and the role of p53 isoforms in cancer progression.
Innovation Solution
A method involving the analysis of biological samples for the presence of specific p53 isoforms (Δ133p53, Δ133p53y, and Δ133p53β) to determine metastatic cancer predisposition, aggressiveness, and response to anti-metastatic therapy, using techniques such as PCR, immunohistochemistry, and mRNA detection to quantify expression levels and compare them to threshold values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (lymph node invasion, histological grade, hormone receptor expression) are used to predict survival, then the assessment is based on well-recognized prognostic factors, but the prediction lacks specificity due to patient heterogeneity
Solution Approach 1:
The invention segments the p53 protein into multiple isoforms (Δ133p53, Δ133p53γ, Δ133p53β) through alternative splicing detection. By analyzing specific isoform patterns rather than total p53 expression, the method distinguishes between different patient subgroups with varying metastatic potentials, thereby improving prognostic precision while accounting for patient heterogeneity.
Solution Approach 2:
The invention focuses on specific local characteristics of p53 isoform expression patterns rather than global protein levels. By detecting the presence and relative abundance of specific isoforms (Δ133p53, Δ133p53γ, Δ133p53β) through RT-PCR and immunohistochemistry, the method provides localized molecular signatures that predict metastatic risk with higher precision across diverse patient populations.
2Reliability
If p53 mutations are used as predictive factors, then the assessment covers the most mutated gene in human tumors, but the predictive value depends on breast cancer types and requires careful interpretation
Solution Approach 1:
The invention extracts and analyzes specific p53 isoform patterns (Δ133p53, Δ133p53γ, Δ133p53β) generated through aberrant splicing, separating these predictive markers from the complex background of total p53 expression and various mutation types. This extraction provides a simplified, reliable predictive signature that maintains high reliability across different breast cancer types while reducing interpretation complexity.
Solution Approach 2:
The invention changes the detection parameter from total p53 protein levels or mutation status to specific isoform expression patterns. By using RT-PCR to detect isoform-specific mRNA and immunohistochemistry to visualize isoform distribution, the method transforms the complex p53 assessment into a standardized parameter (isoform pattern) that provides consistent predictive value across different cancer types with simplified interpretation.
3Adaptability or versatility
If current biomarkers (hormonal receptors, UPA, PAI1, Her2, topoisomerase II α) are used for targeted chemotherapy selection, then treatment can be personalized, but the efficiency depends on cellular characteristics and sensitivity biomarkers that may not capture metastatic potential
Solution Approach 1:
The invention merges the existing personalized therapy framework with novel p53 isoform biomarkers. By combining Δ133p53 isoform detection with current biomarker panels (hormonal receptors, Her2, etc.), the method enhances metastatic risk prediction precision while maintaining personalized therapy adaptability. The p53 isoform pattern serves as an additional layer of molecular characterization that complements existing biomarkers.
Solution Approach 2:
The invention performs preliminary assessment of p53 isoform expression patterns before treatment selection to identify patients at high risk of metastasis. By detecting Δ133p53, Δ133p53γ, and Δ133p53β isoforms upfront through RT-PCR or immunohistochemistry, the method enables early stratification of patients who may benefit from intensified surveillance or adjuvant therapy, improving metastatic risk prediction before treatment decisions are made.
Data Source
Figure 1a~1b
Figure 2a~2b
Figure 3a~3c
AI summary
The present invention concerns a method of testing a subject thought to be predisposed to having a metastatic cancer which comprises the step of i) analyzing a biological sample from said subject for detecting the presence of a p53 isoform selected in the group consisting in ?133p53, ?133p53? and ?133p53ß, the presence of said p53 isoform being indicative of a metastatic cancer.